Transgenic Mouse, ICSI and IVF Core

项目总结/摘要-转基因小鼠、ICSI和IVF核心 转基因小鼠核心是在IBR COBRE的I期期间建立的，基于新的 转座酶介导的基因传递和靶向技术在我们的研究所开发的一个我们的COBRE investigators.在头四年里，核心小组在实现成为 在15年内独立支持。我们已经积累了大量的设备， 显微操作小鼠配子和胚胎培养，并聘请了一位经验丰富的经理， 领导核心实验室在建立核心之前，我们咨询了两个已建立的转基因核心， 其中之一是由内华达州大学支持的COBRE。IBR核心已经取得了很好的进展， 已经产生了36个转基因小鼠品系，并开发了COBRE调查人员 需要核心非常适合提供。核心继续开发新的基因传递 技术，包括在靶向基因插入方面取得重大进展。因此，核心作出了贡献， 通过向COBRE调查人员提供以下信息， 转基因小鼠和其他服务，研究开发和培养下一代科学家。 在第二阶段的申请中，我们建议通过扩展核心服务来增强和改造核心服务， 通过提供：（1）继续研究和开发，以提高转基因小鼠的效率 生产，以及（2）由大学资助的动物和实验室空间的重大翻新， IBR COBRE的机构支持。核心将直接支持四名新的COBRE项目负责人。 由于这种扩展，我们更准确地命名为：转基因小鼠，ICSI和IVF（TMII） 核心Stefan Moisyadi博士是开发基因插入新技术的小组的负责人， 他是一名第一阶段的初级研究员，毕业后独立工作，将成为TMII的核心主任。 这些目标将通过以下具体目标实现：具体目标1。改进TMII核心 通过扩大服务、发展基础设施和翻新核心实验室。核心 将继续使用传统技术提供转基因小鼠， 新技术在这个领域，无论是从我们自己的集团和其他人。我们还将增加新的服务， 作为ICSI和IVF的项目负责人在第二阶段。一个400万美元的翻新UH马诺阿动物园将允许 转基因小鼠的生产效率要高得多。这将是发展的重要一步。 第二阶段的独立性具体目标2。通过新的技术增强和改造IBR TMII核心 IBR COBRE第一阶段开发的技术和基因传递系统的持续发展。 TMII Core将于第二阶段在Dr. 莫瓦夏迪

PROJECT SUMMARY/ABSTRACT - Transgenic Mouse, ICSI and IVF Core The Transgenic Mouse Core was established during Phase I of the IBR COBRE based on novel transposase-mediated gene delivery and targeting technology developed at our institute by one of our COBRE investigators. During the first four years, the Core made significant progress towards the goal of becoming independently supported within fifteen years. We have accumulated a large array of equipment for micromanipulation of mouse gametes and embryo culture, and have recruited an experienced manager to head the Core laboratory. Before establishing the Core, we consulted with two established transgenic cores, one of which was COBRE supported at the University of Nevada. The IBR Core has made excellent progress, having produced 36 transgenic mouse lines, and developed new services that the COBRE investigators required that the Core was well suited to provide. The Core continued the development of novel gene delivery technology, including making significant progress on targeted gene insertion. Thus, the Core has contributed to the enhancement of the institution's research infrastructure by providing the COBRE investigators with transgenic mice and other services, research development, and training the next generation of scientists. In this Phase II application, we propose to enhance and transform the Core by expanding the services it provides through: (1) continued research and development to increase the efficiency of transgenic mouse production, and (2) a major renovation of animal and laboratory space that is being funded by the university as institutional support of the IBR COBRE. The Core will directly support four new COBRE Project Leaders. Because of this expansion, we have more accurately named it: the Transgenic Mouse, ICSI and IVF (TMII) Core. Dr. Stefan Moisyadi, the leader of the group that developed the new technology for gene insertion, and who was a Phase I junior investigator that graduated to independence, will become the TMII Core Director. These goals will be achieved through the following Specific Aims: Specific Aim 1. Improve the TMII Core through expansion of services, infrastructure development and renovation of the core laboratories. The Core will continue to provide transgenic mice using conventional technologies while incorporating rapidly emerging new technologies in the field, both from our own group and from others. We will also add new services such as ICSI and IVF to Project Leaders in Phase II. A $4 million renovation to the UH Manoa vivarium will allow transgenic mice to be produced much more efficiently. This will be an important step towards the development of our independence in Phase II. Specific Aim 2. Enhance and transform the IBR TMII Core through novel technology developed in Phase I of the IBR COBRE and the continued development of gene delivery systems. The TMII Core will continue to develop gene insertion technology during Phase II under the direction of Dr. Moisyadi.